0 CHECKOUT

Shigella Infections (Shigellosis) - Pipeline Review, H1 2015

  • ID: 3196292
  • March 2015
  • 47 pages
  • Global Markets Direct
1 of 4

Shigella Infections (Shigellosis) - Pipeline Review, H1 2015

Summary

This, ‘Shigella Infections (Shigellosis) - Pipeline Review, H1 2015’, provides an overview of the Shigella Infections (Shigellosis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables:

List of Figures:

Introduction

REPORT COVERAGE

Shigella Infections (Shigellosis) Overview

Therapeutics Development

Pipeline Products for Shigella Infections (Shigellosis) - Overview

Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis

Shigella Infections (Shigellosis) - Therapeutics under Development by Companies

Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes

Shigella Infections (Shigellosis) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Shigella Infections (Shigellosis) - Products under Development by Companies

Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes

Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals, Inc.

GlaxoSmithKline plc

GlycoVaxyn AG

Shigella Infections (Shigellosis) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

1790GAHB Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GVXNSD-133 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INX-201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KKL-35 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigella Vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigella vaccine 1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

shigellosis [Shigella flexneri 2a] (whole cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigetec - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Shigellosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit Rns and VirF for Bacterial Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Shigella Infections (Shigellosis) - Recent Pipeline Updates

Shigella Infections (Shigellosis) - Dormant Projects

Shigella Infections (Shigellosis) - Discontinued Products

Shigella Infections (Shigellosis) - Product Development Milestones

Featured News & Press Releases

Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine

Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates

Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions

Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease

Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine

Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Shigella Infections (Shigellosis), H1 2015

Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Investigation by Universities/Institutes, H1 2015

Shigella Infections (Shigellosis) - Pipeline by Anacor Pharmaceuticals, Inc., H1 2015

Shigella Infections (Shigellosis) - Pipeline by GlaxoSmithKline plc, H1 2015

Shigella Infections (Shigellosis) - Pipeline by GlycoVaxyn AG, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H1 2015

Shigella Infections (Shigellosis) - Dormant Projects, H1 2015

Shigella Infections (Shigellosis) - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Shigella Infections (Shigellosis), H1 2015

Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Anacor Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- GlycoVaxyn AG

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.